CA2406395A1 - Nanoparticules renfermant des peptides a haute affinite - Google Patents

Nanoparticules renfermant des peptides a haute affinite Download PDF

Info

Publication number
CA2406395A1
CA2406395A1 CA002406395A CA2406395A CA2406395A1 CA 2406395 A1 CA2406395 A1 CA 2406395A1 CA 002406395 A CA002406395 A CA 002406395A CA 2406395 A CA2406395 A CA 2406395A CA 2406395 A1 CA2406395 A1 CA 2406395A1
Authority
CA
Canada
Prior art keywords
nanoparticle
peptide
polymeric
high affinity
peptide moieties
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002406395A
Other languages
English (en)
Inventor
Stephen E. Barry
Andrew A. Goodwin
Dominic Casenas
Kevin Lindquist
Rachel Decor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alnis BioSciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2406395A1 publication Critical patent/CA2406395A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des nanoparticules polymères fonctionnalisées par au moins deux fractions de peptides possédant une haute affinité avec des cibles biomoléculaires, les fractions de peptides étant liées par covalence à la structure polymère du noyau des nanoparticules, soit de manière directe soit par une molécule de liaison. L'invention concerne également des procédés de synthèse de ces nanoparticules polymères et les différentes applications pour lesquelles elles peuvent être utilisées.
CA002406395A 2000-04-14 2001-04-13 Nanoparticules renfermant des peptides a haute affinite Abandoned CA2406395A1 (fr)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US19776500P 2000-04-14 2000-04-14
US60/197,765 2000-04-14
US22006100P 2000-07-21 2000-07-21
US60/220,061 2000-07-21
US22053000P 2000-07-24 2000-07-24
US60/220,530 2000-07-24
US23644800P 2000-09-29 2000-09-29
US60/236,448 2000-09-29
US25689400P 2000-12-18 2000-12-18
US25681900P 2000-12-18 2000-12-18
US25689500P 2000-12-18 2000-12-18
US60/256,819 2000-12-18
US60/256,894 2000-12-18
US60/256,985 2000-12-21
US26152001P 2001-01-12 2001-01-12
US60/261,520 2001-01-12
PCT/US2001/012093 WO2001078786A2 (fr) 2000-04-14 2001-04-13 Nanoparticules renfermant des peptides a haute affinite

Publications (1)

Publication Number Publication Date
CA2406395A1 true CA2406395A1 (fr) 2001-10-25

Family

ID=27575157

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002406395A Abandoned CA2406395A1 (fr) 2000-04-14 2001-04-13 Nanoparticules renfermant des peptides a haute affinite

Country Status (4)

Country Link
EP (1) EP1276507A2 (fr)
AU (1) AU2001255356A1 (fr)
CA (1) CA2406395A1 (fr)
WO (1) WO2001078786A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1531868A2 (fr) * 2002-06-03 2005-05-25 Alnis Biosciences, Inc. Agents therapeutiques contenant des nano-polymeres
JP4733113B2 (ja) * 2004-05-05 2011-07-27 フイルメニツヒ ソシエテ アノニム 生分解性グラフトコポリマー
US8231907B2 (en) 2006-03-21 2012-07-31 Morehouse School Of Medicine Nanoparticles for delivery of active agents
US10285943B2 (en) 2010-12-02 2019-05-14 Greenmark Biomedical Inc. Aptamer bioconjugate drug delivery device
CN103665117B (zh) * 2013-12-03 2015-07-01 南昌大学 一种高效纯化水溶性纳米银颗粒链霉亲和素偶联物的方法
CN103665118B (zh) * 2013-12-03 2015-11-25 南昌大学 纯化水溶性氧化铁纳米粒子链霉亲和素偶联物的方法
CA3090303A1 (fr) 2018-03-28 2019-10-03 Greenmark Biomedical Inc. Nanoparticule d'amidon reticule au phosphate et traitements dentaires

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732218B1 (fr) * 1995-03-28 1997-08-01 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s) et leurs procedes de preparation

Also Published As

Publication number Publication date
WO2001078786A3 (fr) 2002-08-15
EP1276507A2 (fr) 2003-01-22
WO2001078786A2 (fr) 2001-10-25
AU2001255356A1 (en) 2001-10-30

Similar Documents

Publication Publication Date Title
US20040126900A1 (en) High affinity peptide- containing nanoparticles
US7261875B2 (en) Dendritic poly (amino acid) carriers and methods of use
Chen et al. Recent advances in epsilon-poly-L-lysine and L-lysine-based dendrimer synthesis, modification, and biomedical applications
Kopeček et al. Water soluble polymers in tumor targeted delivery
She et al. PEGylated dendrimer-doxorubicin cojugates as pH-sensitive drug delivery systems: synthesis and in vitro characterization
JP2002543111A (ja) ポリマーを使用する葉酸で仲介された腫瘍細胞へのターゲッティングの増幅
WO2003009881A2 (fr) Nouveaux systemes d'administration ciblee pour agents bioactifs
CA2468548A1 (fr) Copolymere polycationique hydrosoluble et procede de passage de macromolecules polyanioniques a travers des barrieres biologiques
WO2009001364A2 (fr) Ciblage de conjugués renfermant des agents actifs encapsulés dans des polymères contenant de la cyclodextrine
WO2003082348A1 (fr) Reseaux de nanogel comprenant des fragments polymeres polyioniques et compositions d'agents biologiques de ceux-ci
EP1578450A1 (fr) Amplification du ciblage medie par la biotine
Mariyam et al. Dendrimers: general aspects, applications and structural exploitations as prodrug/drug-delivery vehicles in current medicine
Niederhafner et al. Glycopeptide dendrimers. Part II
JP2003531930A (ja) 両親媒性大環状誘導体およびそれらの類似体
WO2003101425A2 (fr) Articles polymeres contenant des agents therapeutiques
Riber et al. Recent advances in macromolecular prodrugs
Duncan N-(2-Hydroxypropyl) methacrylamide copolymer conjugates
Vaidya et al. Bioconjugation of polymers: a novel platform for targeted drug delivery
CA2553647A1 (fr) Articles comprenant un materiau magnetique et des agents bioactifs
Steiert et al. pH-Responsive protein nanoparticles via conjugation of degradable PEG to the surface of cytochrome c
CA2406395A1 (fr) Nanoparticules renfermant des peptides a haute affinite
JP2004500438A (ja) 高親和性のペプチド含有ナノ粒子
Lukyanov et al. PEGylated dextran as long-circulating pharmaceutical carrier
WO1998013069A2 (fr) Complements pharmaceutiques copolymeriques fluores
US20050129769A1 (en) Polymeric articles for carrying therapeutic agents

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20070413